A Phase 1-2 Study of ODM-212 in People With Advanced Solid Tumors

Full Title

Purpose

Researchers want to find the best dose of ODM-212 to treat advanced solid tumors. The people in this study have solid tumors that have spread and cannot be cured with standard therapies. Examples include:

• Mesothelioma
• Epithelioid hemangioendothelioma
• Schwannoma
• Meningioma
• Renal cell cancer 
• Bile duct cancer
• Head and neck cancer
• Lung cancer
• Colorectal cancer
• Liver cancer
• Prostate cancer

ODM-212 blocks a family of proteins called TEADs. These proteins help turn genes on or off. In healthy cells, TEADs help control normal growth. But in cancer cells, TEADs can get help from another protein that tells them to stay switched on all the time.

By blocking TEADs, ODM-212 may help slow or stop the growth of your cancer. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have a solid tumor that spread and keeps growing after or cannot be treated with standard therapies.
• Have finished prior medical treatments for cancer at least 2 weeks before taking ODM-212 (4 weeks since radiation therapy or major surgery).
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call 646-888-4226.